Core Concepts
Nirmatrelvir-ritonavir does not reduce most post-COVID conditions except for thromboembolic events.
Abstract
TOPLINE:
Study on 9593 veterans over 65 years.
Nirmatrelvir-ritonavir impact on post-COVID conditions.
Thromboembolic events exception.
METHODOLOGY:
Retrospective study on PCCs.
31 conditions analyzed across various categories.
Incidence analyzed 31 to 180 days post-treatment.
TAKEAWAY:
Reduced incidence of venous thromboembolism and pulmonary embolism.
No significant reduction in other conditions.
Results differ from a smaller study.
IN PRACTICE:
PCCs may not be crucial in COVID-19 treatment decisions.
SOURCE:
Study funded by US Department of Veterans Affairs.
Published in Annals of Internal Medicine on October 30.
Led by George Ioannou, MD.
LIMITATIONS:
Association between treatment and reduced incidence may be by chance.
Data on treatments and PCCs may be incomplete.
Long-term effects of PCCs not fully captured.
DISCLOSURES:
Authors' relationships with various associations.
Stats
A retrospective study of 9593 veterans older than 65 years.
The incidence of PCCs was analyzed 31 to 180 days after treatment.
Results differ from a smaller study that found lower incidence of 10 of 13 PCCs.
Quotes
"Our results suggest that considerations about PCCs may not be an important factor in COVID-19 treatment decisions." - Study Authors